Space Scotland names new CEO to steer thriving space sector
Space Scotland, a not-for-profit company, was founded in 2021 and supports Scotland's space industry, academia, and government representatives in a bid to further develop the country's space sector.
Dr Nicholson's appointment comes at a pivotal moment for Scotland's space ambitions, with Europe's first-ever commercial launch into orbit expected to take place from Shetland in the months ahead.
READ MORE: History made as Scottish rocket firm hits 'major milestone'
'There's so much potential, so much existing, fantastic work being done here in Scotland and so much potential to take it further as well,' Dr Nicholson told The National.
With a surge in commercial activity across research, manufacturing, and satellite data analysis, Scotland now hosts more than 180 space organisations and leads Europe in the manufacture of small satellites, with firms like Spire Global, AAC Clyde Space, and Alba Orbital all operating from Glasgow alone.
Dr Nicholson (below) said her vision for the future includes continuing to support the 'amazing satellite manufacturing' that Scottish firms are currently producing and wants to further the 'attractiveness' Scotland offers to international firms to invest in the country.
(Image: Space Scotland)
She added that Scotland's space sector has already made an amazing contribution for 'a small European country' and insisted that Scotland has 'strengths in so many other areas beyond space as well,' as she lists advanced manufacturing, AI, and robotics as core strengths for the country.
Dr Nicholson also praised Scotland's space community for its collaborative approach with its industry working in partnership with many of its universities and colleges, along with Scottish Enterprise and the UK Space Agency.
'It's been a very collaborative approach to things, and it would be a real shame not to have that approach because there are so many fantastic organisations and great strengths here in Scotland, and that pooling our resources is always going to give us better results,' Dr Nicholson said.
She added: 'There's a lot to be done and I think Scotland can really be at the forefront of some of the new emerging sectors, sort of subspace sectors as well, like in space manufacturing.'
Dr Nicholson, who is returning to Space Scotland after leaving to run her own firm for a while, said she had 'really fond memories' of the organisation and of the Scottish space community.
Space Scotland chair and board director Peter Young welcomed Dr Nicholson's appointment as he said: 'Scotland's space industry offers major opportunities across sustainability, launch, data and advanced manufacturing, while also enabling innovation in sectors like life sciences, AI and fintech.
'Natasha is the right person to help us harness that potential. Her scientific knowledge, delivery focus, and strong network made her an outstanding choice.'
Young added there's a huge job to be done in promoting Scotland's thriving space sector as he said people are quick to jump to the idea of something like Elon Musk taking people to Mars or something else 'fanatical' when there are a lot of real-world applications which benefit immensely from the sector growing.
'Actually, literally, it's more down to earth than that in terms of what this space industry is and what it can bring,' he said.
'It can add value to daily life stuff in terms of what's happening here in Scotland.'
Young (below) said that, while there are plans for Scotland to have its first commercial take off in the near future, 'it's not all about missions to Mars or asteroids'.
(Image: Space Scotland)
He said: 'There's something much more valuable and concrete in terms of what space can deliver.'
When Dr Nicholson was last with Space Scotland, she helped establish a pilot where students from universities and colleges worked with the space industry to get real-life experience and said she hopes to introduce more similar initiatives to get Scots involved.
The initiative was designed to be more practical and transitional for people who had either just come out of university or had graduated with a more general engineering background, so they could learn more specifics around skills for the likes of satellite manufacturing and other space sectors.
With a PhD in astrobiology, Dr Nicholson has held roles including Cross-Cluster Liaison Manager for the Science and Technology Facilities Council at Harwell Campus, Chief Scientific Officer for the Arctic research station, and CEO for a space-related research and development business.
She will now lead the next phase of development for Space Scotland, bringing focus to the delivery of the national strategy.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Reuters
5 minutes ago
- Reuters
European shares end flat as healthcare stocks weigh after Trump's tariff threat
Aug 6 (Reuters) - European shares closed flat on Wednesday, surrendering early session gains, as healthcare stocks felt the pinch from U.S. President Donald Trump's latest threat to impose higher tariffs on pharmaceutical imports. The pan-European STOXX 600 (.STOXX), opens new tab index closed 0.06% lower, breaking its two-day winning streak despite starting the session on a positive note. Healthcare stocks bore the brunt of the selling pressure. The sector index (.SXDP), opens new tab plunged 2.8% to its lowest level in more than three months after Trump unveiled a graduated tariff plan targeting pharmaceutical imports that could see levies on the sector jump up to 250% within 18 months. "This is where it's important to be specific about tariffs because certain stocks and sectors will be impacted differently across regions," said Steve Sosnick, chief market analyst at Interactive Brokers. "In Europe and Asia, investors are considering tariff impacts more carefully since exporters bear much of the brunt directly." The sector was also singed as Novo Nordisk ( opens new tab warned it expects continued competition from copycat versions of its Wegovy obesity drug this year, a message that sent shares of the Danish drug maker down 5.4%. Novo cut its full-year sales and profit forecasts last week, wiping $95 billion off its market value since then. Meanwhile, Swiss President Karin Keller-Sutter met with U.S. Secretary of State Marco Rubio to discuss potential trade solutions after Trump announced a 39% tariff on Swiss goods. The talks focused on increasing Swiss purchases of U.S. energy and defence products to avert the steep tariff, which threatens significant damage to Switzerland's export-driven economy. Switzerland's benchmark SMI index (.SSMI), opens new tab fell 0.9%, weighed down by drugmakers Novartis (NOVN.S), opens new tab and Roche (ROG.S), opens new tab which lost 3.3% and 2.6%, respectively. Bayer ( opens new tab shares tumbled 9.9% on investor concerns that the German pharmaceutical firm's earnings were inflated by soccer player transfer fees rather than supported by its core healthcare and agriculture businesses. On the data front, Euro zone retail sales grew quicker than thought in June, reinforcing views that the 27-nation bloc remains resilient to trade uncertainty. Among others, Beiersdorf ( opens new tab fell 8.4% and was among top decliners after the German consumer goods maker cut its annual organic sales growth outlook. On the flip side, Siemens Energy ( opens new tab rose 1% after the company said it expects to hit the upper end of its 2025 growth outlook estimates. Hiscox (HSX.L), opens new tab was the top gainer on the index, gaining 9.4% after reporting a rise in first-half insurance premiums supported by its retail business growth.
Glasgow Times
29 minutes ago
- Glasgow Times
People with ME have key genetic differences to other people, study finds
Scientists said the findings offer the first robust evidence that genes contribute to a person's chance of developing the disease. The DecodeME study, said to be the largest of its kind in the world, uncovered eight areas of genetic code in people with ME/CFS (myalgic encephalomyelitis/chronic fatigue syndrome) that are markedly different to the DNA of people without the condition. Researchers hope the findings will boost 'validity and credibility' for patients, and help rebuff some of the stigma and lack of belief that exists around the condition. There is currently no diagnostic test or cure for ME/CFS, which is believed to affect around 67 million people worldwide, and very little is known about what causes it. A key feature of the condition is a disproportionate worsening of symptoms following even minor physical or mental activity, which is known as post-exertional malaise (PEM,) while other symptoms include pain, brain fog and extreme energy limitations that do not improve with rest. For the new study, researchers analysed 15,579 DNA samples from the 27,000 people with ME/CFS participating in DecodeME, described as the world's largest data set of people with the disease. The eight regions of DNA where scientists found genetic differences involve genes linked to the immune and nervous systems. At least two of the genetic signals relate to how the body responds to infection, which researchers said aligns with long-standing patient reports that the onset of symptoms often followed an infectious illness. Professor Chris Ponting, DecodeME investigator from the University of Edinburgh, said: 'This is a wake-up call. These extraordinary DNA results speak the language of ME/CFS, often recounting people's ME/CFS symptoms. 'DecodeME's eight genetic signals reveal much about why infection triggers ME/CFS and why pain is a common symptom. 'ME/CFS is a serious illness and we now know that someone's genetics can tip the balance on whether they are diagnosed with it.' As a person's DNA does not change over time, experts say the genetic signals identified would not have developed because of ME/CFS and are therefore likely to reflect the causes of the disease. Populations used in the initial study were limited to those from European ancestries. DecodeME research studying DNA data from all ancestries is ongoing. ME/CFS, thought to affect around 404,000 people in the UK, affects more females than males, although researchers found nothing to explain why this is the case. The DecodeME team is now calling on researchers from around the world to access its 'rich' dataset and help drive forward targeted studies into ME/CFS. Sonya Chowdhury, chief executive of Action for ME and a DecodeME co-investigator, said: 'These results are groundbreaking. 'With DecodeME, we have gone from knowing next to nothing about the causes of ME/CFS, to giving researchers clear targets.' She also hopes the discoveries will help change the way the condition is viewed. Ms Chowdhury said: 'This really adds validity and credibility for people with ME. 'We know that many people have experienced comments like ME is not real, or they've been to doctors and been disbelieved or told that it's not a real illness. 'Whilst things have changed and continue to change, that is still the case for some people and we hear that repeatedly as a charity. Researchers at the University of Edinburgh are involved in the study (Jane Barlow/PA) 'Being able to take this study into the treatment room and say there are genetic causes that play a part in ME is going to be really significant for individuals. 'It will rebuff that lack of belief and the stigma that exists.' The findings have been reported in a pre-print publication, or unpublished study. During a media briefing about the study, researchers were asked about similarities between the symptoms of long Covid and ME/CFS. Prof Ponting said: 'It's very clear that the symptomology between long Covid and ME is highly similar. 'Not for everyone but there are substantial similarities but as a geneticist the key question for me is are there overlapping genetic factors, and we haven't found that in DECode ME with the methods that we've employed. 'One of the key things that we're doing is enabling others to use their different approaches to ask and answer the same question.' DecodeME is a collaboration between the University of Edinburgh, the charity Action for ME, the Forward ME alliance of charities, and people with ME/CFS. It is funded by the Medical Research Council and National Institute for Health and Care Research.
STV News
31 minutes ago
- STV News
People with ME have key genetic differences to other people, study finds
People diagnosed with ME/chronic fatigue syndrome (CFS) have significant differences in their DNA compared to those without the condition, according to a 'groundbreaking' new study. Scientists said the findings offer the first robust evidence that genes contribute to a person's chance of developing the disease. The DecodeME study, said to be the largest of its kind in the world, uncovered eight areas of genetic code in people with ME/CFS (myalgic encephalomyelitis/chronic fatigue syndrome) that are markedly different to the DNA of people without the condition. Researchers hope the findings will boost 'validity and credibility' for patients, and help rebuff some of the stigma and lack of belief that exists around the condition. There is currently no diagnostic test or cure for ME/CFS, which is believed to affect around 67 million people worldwide, and very little is known about what causes it. A key feature of the condition is a disproportionate worsening of symptoms following even minor physical or mental activity, which is known as post-exertional malaise (PEM,) while other symptoms include pain, brain fog and extreme energy limitations that do not improve with rest. For the new study, researchers analysed 15,579 DNA samples from the 27,000 people with ME/CFS participating in DecodeME, described as the world's largest data set of people with the disease. The eight regions of DNA where scientists found genetic differences involve genes linked to the immune and nervous systems. At least two of the genetic signals relate to how the body responds to infection, which researchers said aligns with long-standing patient reports that the onset of symptoms often followed an infectious illness. Professor Chris Ponting, DecodeME investigator from the University of Edinburgh, said: 'This is a wake-up call. These extraordinary DNA results speak the language of ME/CFS, often recounting people's ME/CFS symptoms. 'DecodeME's eight genetic signals reveal much about why infection triggers ME/CFS and why pain is a common symptom. 'ME/CFS is a serious illness and we now know that someone's genetics can tip the balance on whether they are diagnosed with it.' As a person's DNA does not change over time, experts say the genetic signals identified would not have developed because of ME/CFS and are therefore likely to reflect the causes of the disease. Populations used in the initial study were limited to those from European ancestries. DecodeME research studying DNA data from all ancestries is ongoing. ME/CFS, thought to affect around 404,000 people in the UK, affects more females than males, although researchers found nothing to explain why this is the case. The DecodeME team is now calling on researchers from around the world to access its 'rich' dataset and help drive forward targeted studies into ME/CFS. Sonya Chowdhury, chief executive of Action for ME and a DecodeME co-investigator, said: 'These results are groundbreaking. PA Media Researchers at the University of Edinburgh are involved in the study. 'With DecodeME, we have gone from knowing next to nothing about the causes of ME/CFS, to giving researchers clear targets.' She also hopes the discoveries will help change the way the condition is viewed. Ms Chowdhury said: 'This really adds validity and credibility for people with ME. 'We know that many people have experienced comments like ME is not real, or they've been to doctors and been disbelieved or told that it's not a real illness. 'Whilst things have changed and continue to change, that is still the case for some people and we hear that repeatedly as a charity. 'Being able to take this study into the treatment room and say there are genetic causes that play a part in ME is going to be really significant for individuals. 'It will rebuff that lack of belief and the stigma that exists.' The findings have been reported in a pre-print publication, or unpublished study. During a media briefing about the study, researchers were asked about similarities between the symptoms of long Covid and ME/CFS. Prof Ponting said: 'It's very clear that the symptomology between long Covid and ME is highly similar. 'Not for everyone but there are substantial similarities but as a geneticist the key question for me is are there overlapping genetic factors, and we haven't found that in DECode ME with the methods that we've employed. 'One of the key things that we're doing is enabling others to use their different approaches to ask and answer the same question.' DecodeME is a collaboration between the University of Edinburgh, the charity Action for ME, the Forward ME alliance of charities, and people with ME/CFS. It is funded by the Medical Research Council and National Institute for Health and Care Research. Get all the latest news from around the country Follow STV News Scan the QR code on your mobile device for all the latest news from around the country
